Nothing said here yet.
to join the conversation.
| LYNCH TIMOTHY P | Buy | 1,150,000 | $243.5K | Wed, Aug 19 |
HONG KONG, Oct. 23, 2026 /PRNewswire/ -- AEON, the settlement layer built for the AI economy, has launched Agentic Checkout V2, expanding its agentic commerce infrastructure beyond e-commerce purchases to travel bookings.
By John Vandermosten, CFA NYSE: AEON READ THE FULL AEON RESEARCH REPORT We are initiating coverage of AEON Biopharma, Inc. (NYSE: AEON) with a valuation of $2.00 per share.
FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026 AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined development path ALISO VIEJO, Calif., Sept.
HONG KONG, Sept. 4, 2026 /PRNewswire/ -- AEON, the settlement layer built for the AI economy, has launched Agentic Checkout, enabling AI agents to autonomously shop, check out, and pay across e-commerce platforms such as Shopify and Amazon.
ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc.
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary analysis demonstrates preservation of the…
- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - Upfront proceeds from financing provide cash runway into the first quarter of 2027 ALISO VIEJO, Calif., Aug.
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc.
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offeringIRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc.